Background The medial temporal region is the earliest affected structure in patients with Alzheimer’s disease (AD), and its atrophy is known as the hallmark of AD. This study aimed to investigate the value of medial temporal atrophy (MTA) for detecting 18F-florbetaben positron emission tomography (PET)-proven AD pathology.
Methods We retrospectively enrolled 265 subjects complaining of cognitive decline at a dementia outpatient clinic from March 2015 to December 2017. All subjects underwent brain magnetic resonance imaging, 18F-fluorodeoxyglucose PET, and 18F-florbetaben PET at baseline. We performed multivariable logistic regression analyses on variables including age, sex, years of education, white matter hyperintensities, apolipoprotein E (APOE) genotype, and memory composite scores in various combinations to investigate whether MTA was indicative of underlying AD pathology.
Results Our sample population of 265 patients comprised 121 with AD-related cognitive impairment, 42 with Lewy bodies-related cognitive impairment, 32 with vascular cognitive impairment, and 70 with other or undetermined pathologies. In the multivariable logistic regression analyses, MTA was not an independent predictor of underlying AD pathology (P>0.200). The predictive power of underlying AD-related cognitive impairment significantly increased when multiple variables including APOE genotype and memory composite scores were considered together (area under the curve >0.750).
Conclusion Our results suggest that MTA alone may be insufficient to accurately predict the presence of AD pathology. It is necessary to comprehensively consider various other factors such as APOE genotype and a detailed memory function to determine whether the patient is at high risk of AD.
Citations
Citations to this article as recorded by
Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting A. Zilioli, A. Rosenberg, R. Mohanty, A. Matton, T. Granberg, G. Hagman, J. Lötjönen, M. Kivipelto, E. Westman Journal of Neurology.2025;[Epub] CrossRef
CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome Durjoy Lahiri, Bruna Seixas-Lima, Carlos Roncero, Nicolaas Paul Verhoeff, Morris Freedman, Sarmad Al-Shamaa, Howard Chertkow Frontiers in Neurology.2024;[Epub] CrossRef
White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers Ming-Chun Yu, Yi-Fang Chuang, Shu-Ching Wu, Cheng-Feng Ho, Yi-Chien Liu, Chia-Ju Chou Frontiers in Neurology.2023;[Epub] CrossRef
Brain atrophy pattern in patients with mild cognitive impairment: MRI study Rosalinda Calandrelli, Marco Panfili, Valeria Onofrj, Huong Elena Tran, Francesca Piludu, Valeria Guglielmi, Cesare Colosimo, Fabio Pilato Translational Neuroscience.2022; 13(1): 335. CrossRef